The benefits of ischemic preconditioning (IPC) in reducing ischemia/reperfusion injury (IRI) remain indistinct in human liver transplantation (LT). To further understand mechanistic aspects of IPC, we performed microarray analyses as a nested substudy in a randomized trial of 10-minute IPC in 101 de
Ischemic preconditioning in deceased donor liver transplantation: A prospective randomized clinical trial of safety and efficacy
โ Scribed by Baburao Koneru; Adrian Fisher; Yan He; Kenneth M. Klein; Joan Skurnick; Dorian J. Wilson; Andrew N. de la Torre; Anand Merchant; Rakesh Arora; Arun K. Samanta
- Publisher
- John Wiley and Sons
- Year
- 2005
- Tongue
- English
- Weight
- 92 KB
- Volume
- 11
- Category
- Article
- ISSN
- 1527-6465
- DOI
- 10.1002/lt.20315
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
The effect of ischemic preconditioning (IPC) in orthotopic liver transplantation (OLT) has not yet been clarified. We performed a pilot study to evaluate the effects of IPC in OLT by comparing the outcomes of recipients of grafts from deceased donors randomly assigned to receive (IPCฯฉ group, n ฯญ 23)
Ischemic preconditioning (IP) is an effective method for protecting organs from ischemia/reperfusion (IR) injury; however, the molecular basis of this protective effect is poorly understood. This study assessed the gene expression profile in liver allografts during transplantation and evaluated the
Acute cellular rejection (ACR) after orthotopic liver transplantation occurs in 50% to 80% of patients despite the recent advances in immunosuppressive therapy. Adjuvant use of ursodeoxycholic acid (UDCA) is theoretically attractive, but studies have shown conflicting results. In this randomized, co
Maintenance of adequate immunosuppression and avoidance of side-effects are the goals of long-term management of all organ-transplanted patients. We here report the final results of a prospective, randomized trial comparing early cyclosporine monotherapy versus double-drug therapy (cyclosporine and